Novel treatment options in lymphoma and leukemia 1

Published on May 29, 2017   32 min
0:00
Hello everyone. My name is Nishitha Reddy and I'm the Associate Professor of Medicine at Vanderbilt University Medical Center and the Director of the Lymphoma Program here. Today we'll be discussing the novel treatment options that are available for lymphoma and leukemia treatments.
0:19
So in the last decade, we have seen an emergence of several new drugs that have been approved for both Hodgkin and non-Hodgkin lymphoma, and most of these agents are targeted therapies that were designed to alter a specific pathway or antibodies that bind to a particular site. As we can see here, several novel agents have been approved since 2008 up until now. Starting in 2008, bendamustine was approved for relapsed indolent lymphomas. And following that, several new agents have been approved specifically obinutuzumab, which is one of the novel monoclonal antibody therapies for approval in CLL and relapsed follicular lymphoma in combination with bendamustine. Another agent is brentuximab, which was approved in 2011 for Hodgkin lymphoma. And more recently some of the novel agents such as PD-1 inhibitors, specifically nivolumab and pembrolizumab have been given accelerated approval for Hodgkin lymphoma. So in the next several slides, we will be discussing the mechanisms of action of these agents, the current indications, the side effects of novel agents used in the treatment of lymphomas and leukemias.
Hide

Novel treatment options in lymphoma and leukemia 1

Embed in course/own notes